Strongbridge Biopharma: Commercial stage company focused on rare diseases. Topline placebo-controlled Ph3 LOGICS data expected Q3 for RECORLEV™, cortisol synthesis inhibitor for endogenous Cushing's syndrome. Enrollment completion announced May 11, 2020. KEVEYIS® is first and only approved drug for Primary Periodic Paralysis (PPP); Q1'20 revenue up 54% from Q1'19 and guiding to FY20 revenue of $22M-$26M.
Based in...
US - Middle Atlantic
Clinical Stage
Disease Space
Central Nervous System, Rare Disease
Public, USA
Market Cap
100MM - 500MM
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Strongbridge Biopharma plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Caxton Corp. 12.21 6,612,065 25.39 13F 2020-03-31
NEA Management Co. 7.64 4,141,308 15.90 13F 2020-03-31
Ikarian Capital LLC 6.26 3,392,787 13.03 13F 2020-03-31
The Vanguard Group, Inc. 3.34 1,807,339 6.94 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 3.25 1,760,905 6.76 13F 2020-03-31
BlackRock Fund Advisors 2.68 1,449,747 5.57 13F 2020-03-31
Hudson Bay Capital Management LP 2.60 1,409,419 5.41 13F 2020-03-31
Renaissance Technologies LLC 1.78 964,328 3.70 13F 2020-03-31
State Street Corp. 1.40 756,940 2.91 13F 2020-03-31
Broadfin Capital LLC 1.11 600,000 2.30 Stakes 2019-12-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.